Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gosuranemab (BIIB092) MAD Study in PSP
NCT02460094Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gosuranemab in progressive supranuclear palsy (PSP) (4 arms), sponsored by Biogen. Primary endpoint: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Oct 2015; status: completed.
02
Drugs
gosuranemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02460094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460094.